Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors

被引：3
作者：
Mansour, Mai A. [1 ]
Hassan, Ghaneya S. [1 ,2 ]
Serya, Rabah A. T. [3 ]
Jaballah, Maiy Y. [3 ]
Abouzid, Khaled A. M. [3 ]
机构：
[1] Badr Univ Cairo, Sch Pharm, Pharmaceut Chem Dept, Cairo, Egypt
[2] Cairo Univ, Fac Pharm, Pharmaceut Chem Dept, Cairo, Egypt
[3] Ain Shams Univ, Fac Pharm, Pharmaceut Chem Dept, Cairo, Egypt
来源：
BIOORGANIC CHEMISTRY | 2024年 / 147卷
关键词：
TGF-beta; ALK5; inhibitors; Binding interactions; Structure-activity relationship; TGF-BETA RECEPTOR; TO-MESENCHYMAL TRANSITION; SMALL-MOLECULE INHIBITOR; I RECEPTOR; BIOLOGICAL EVALUATION; DOMAIN INHIBITORS; POTENT; DESIGN; FIBROSIS; DERIVATIVES;
D O I：
10.1016/j.bioorg.2024.107332
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Activin receptor-like kinase-5 (ALK5) is an outstanding member of the transforming growth factor-beta (TGF-beta) family. (TGF-beta) signaling pathway integrates pleiotropic proteins that regulate various cellular processes such as growth, proliferation, and differentiation. Dysregulation within the signaling pathway can cause variety of diseases, such as fibrosis, cardiovascular disease, and especially cancer, rendering ALK5 a potential drug target. Hence, various small molecules have been designed and synthesized as potent ALK5 inhibitors. In this review, we shed light on the current ATP-competitive inhibitors of ALK5 through diverse heterocyclic based scaffolds that are in clinical or pre-clinical phases of development. Moreover, we focused on the binding interactions of the compounds to the ATP binding site and the structure-activity relationship (SAR) of each scaffold, revealing new scopes for designing novel candidates with enhanced selectivity and metabolic profiles.
引用
收藏
页数：16
相关论文
共 108 条
  • [1] Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
    Amada, Hideaki
    Asanuma, Hajime
    Koami, Takeshi
    Okada, Atsushi
    Endo, Mayumi
    Ueda, Yasuji
    Naruse, Takumi
    Ikeda, Akiko
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2013, 61 (03) : 286 - 291
  • [2] 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-β type I receptor inhibitors
    Amada, Hideaki
    Sekiguchi, Yoshinori
    Ono, Naoya
    Koami, Takeshi
    Takayama, Tetsuo
    Yabuuchi, Tetsuya
    Katakai, Hironori
    Ikeda, Akiko
    Aoki, Mari
    Naruse, Takumi
    Wada, Reiko
    Nozoe, Akiko
    Sato, Masakazu
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (24) : 7128 - 7138
  • [3] Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase
    Amada, Hideaki
    Sekiguchi, Yoshinori
    Ono, Naoya
    Matsunaga, Yuko
    Koami, Takeshi
    Asanuma, Hajime
    Shiozawa, Fumiyasu
    Endo, Mayumi
    Ikeda, Akiko
    Aoki, Mari
    Fujimoto, Natsuko
    Wada, Reiko
    Sato, Masakazu
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (05) : 2024 - 2029
  • [4] [Anonymous], 2005, [No title captured], Patent No. [2005103028A1, 2005103028]
  • [5] ALK5 inhibitor acts on trabecular meshwork cell and reduces intraocular pressure
    Aoshima, Kota
    Inagaki, Satoshi
    Takagi, Yuya
    Nakamura, Shinsuke
    Hara, Hideaki
    Shimazawa, Masamitsu
    [J]. EXPERIMENTAL EYE RESEARCH, 2023, 227
  • [6] 2-Aminoimidazoles inhibitors of TGF-β receptor 1
    Bonafoux, Dominique
    Chuaqui, Claudio
    Boriack-Sjodin, P. Ann
    Fitch, Chris
    Hankins, Gretchen
    Josiah, Serene
    Black, Cheryl
    Hetu, Gregg
    Ling, Leona
    Lee, Wen-Cherng
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (03) : 912 - 916
  • [7] Progressive transforming growth factor β1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor
    Bonniaud, P
    Margetts, PJ
    Kolb, M
    Schroeder, JA
    Kapoun, AM
    Damm, D
    Murphy, A
    Chakravarty, S
    Dugar, S
    Higgins, L
    Protter, AA
    Gauldie, J
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (08) : 889 - 898
  • [8] Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring
    Boys, Mark L.
    Bian, Feng
    Kramer, James B.
    Chio, Christopher L.
    Ren, Xiao-Dan
    Chen, Huifen
    Barrett, Stephen D.
    Sexton, Karen E.
    Iula, Donna M.
    Filzen, Gary F.
    Nguyen, Maria N.
    Angell, Paul
    Downs, Victoria L.
    Wang, Zhi
    Raheja, Neil
    Ellsworth, Edmund L.
    Fakhoury, Stephen
    Bratton, Larry D.
    Keller, Paul R.
    Gowan, Richard
    Drummond, Elena M.
    Maiti, Samarendra N.
    Hena, Mostofa A.
    Lu, Leroy
    McConnell, Patrick
    Knafels, John D.
    Thanabal, Venkataraman
    Sun, Fang
    Alessi, Diane
    McCarthy, Ann
    Zhang, Erli
    Finzel, Barry C.
    Patel, Sneha
    Ciotti, Susan M.
    Eisma, Rone
    Payne, N. A.
    Gilbertsen, Richard B.
    Kostlan, Catherine R.
    Pocalyko, David J.
    Lala, Deepak S.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (10) : 3392 - 3397
  • [9] Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice
    Bueno, Lorea
    de Alwis, Dinesh P.
    Pitou, Celine
    Yingling, Jonathan
    Lahn, Michael
    Glatt, Sophie
    Troconiz, Inaki F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 142 - 150
  • [10] SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7
    Byfield, SD
    Major, C
    Laping, NJ
    Roberts, AB
    [J]. MOLECULAR PHARMACOLOGY, 2004, 65 (03) : 744 - 752
12345678910